PAUL J. DIAZ - 13 May 2024 Form 4 Insider Report for MYRIAD GENETICS INC (MYGN)

Signature
By: Justin Hunter For: Paul J. Diaz
Issuer symbol
MYGN
Transactions as of
13 May 2024
Net transactions value
-$5,728,763
Form type
4
Filing time
15 May 2024, 17:49:23 UTC
Previous filing
25 Mar 2024
Next filing
14 Aug 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MYGN Common Stock Sale $1,453,550 -57,844 -4.5% $25.13 1,236,166 13 May 2024 Direct F1
transaction MYGN Common Stock Sale $2,394,798 -95,000 -7.7% $25.21 1,141,166 14 May 2024 Direct F2
transaction MYGN Common Stock Sale $1,880,415 -75,000 -6.6% $25.07 1,066,166 15 May 2024 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.83, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.915 to $25.49, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.64 to $25.60, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.